Studying Serum Catestatin Levels in Adults with Moderate to Severe Acne Vulgaris Before and After Oral Isotretinoin Treatment

What this Trial Is About

Acne vulgaris is a common inflammatory skin condition affecting the hair follicles, mostly seen in teenagers and young adults aged 12 to 24. This study focuses on adults aged 18 to 40 with moderate to severe acne, aiming to assess serum catestatin levels, a peptide involved in immunity and inflammation, before and after treatment. Researchers investigate the relationship between catestatin and acne severity, along with the response to oral isotretinoin treatment. Participants are divided into two groups around 30 patients with moderate to severe acne and about 30 healthy individuals. The study evaluates serum catestatin levels and the effects of oral isotretinoin, a medication known to reduce acne severity, over a 12-week period. The trial compares catestatin levels between acne sufferers and healthy controls and monitors changes after isotretinoin treatment. During the study, participants will have blood samples taken to measure catestatin levels and undergo evaluations related to acne severity. The primary outcomes include changes in catestatin levels and the clinical effects of isotretinoin after 12 weeks. The trial runs from January 2025 to January 2026, involving random assignment to study or control groups, with no masking applied.

Assessment of Serum Catestatin Level in Acne Vulgaris Patients